{"id":6692,"date":"2022-01-13T17:42:00","date_gmt":"2022-01-13T17:42:00","guid":{"rendered":"https:\/\/www.capgemini.com\/ca-fr\/?post_type=research-and-insight&#038;p=672749"},"modified":"2023-11-09T06:22:37","modified_gmt":"2023-11-09T06:22:37","slug":"digital-therapeutics","status":"publish","type":"research-and-insight","link":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/","title":{"rendered":"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical"},"content":{"rendered":"\n<header class=\"wp-block-cg-blocks-hero-reusable header heroReusable  \"><div class=\"header-bgs\"><picture><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=2880&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=2880&amp;quality=70 2x\" media=\"(min-width: 1500px)\"\/><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=1440&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=2880&amp;quality=70 2x\" media=\"(min-width: 992px)\"\/><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=1024&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=1024&amp;quality=70 2x\" media=\"(min-width: 768px)\"\/><source srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=768&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png?w=768&amp;quality=70 2x\" media=\"(min-width: 0)\"\/><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/2022-FR-FI-DTx.png\" class=\"header-img header-img-d\" alt=\"\" style=\"object-fit:cover;object-position:50% 50%\" loading=\"eager\"\/><\/picture><\/div><div class=\"heroPictureCardHeaderShape\"><\/div><div class=\"container\"><div class=\"row\"><div class=\"col-md-12\"><div class=\"box\"><div class=\"boxTagWrapper\"><div class=\"tagInfo\"><div><span class=\"box-tag\">Life Sciences<\/span><\/div><\/div><div class=\"brandInfo\"><div class=\"brandLogo\"><img decoding=\"async\" loading=\"lazy\" src=\"\/wp-content\/themes\/capgemini2020\/assets\/images\/capgemini-invent.svg\" alt=\"capgemini-invent\"\/><\/div><\/div><\/div><div class=\"box-title\"><h1 data-maxlength=\"34\">Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical<\/h1><\/div><div class=\"inner-row-insight download-btn\"><div class=\"col-md-4 downloadFiles addPadding\"><a class=\"button-download--small\" type=\"download\" href=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/04\/PoV_Invent-Digital-Therapeutics_Def.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><span>Point de Vue<\/span><span class=\"type\">2 MB  pdf<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/header>\n\n\n\n<section class=\"wp-block-cg-blocks-intro-para undefined section section--intro\"><div class=\"intro-para\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-1\"><nav class=\"article-social\"><ul class=\"social-nav\"><li class=\"ip-order-fb\"><a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/digital-therapeutics\/\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-fb\"><\/i><span class=\"sr-only\">Facebook<\/span><\/a><\/li><li class=\"ip-order-li\"><a href=\"https:\/\/www.linkedin.com\/sharing\/share-offsite\/?url=https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/digital-therapeutics\/\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Ouvrir dans une nouvelle fen\u00eatre\"><i aria-hidden=\"true\" class=\"icon-li\"><\/i><span class=\"sr-only\">Linkedin<\/span><\/a><\/li><\/ul><\/nav><\/div><div class=\"col-12 col-md-11 col-lg-10\"><h2 class=\"intro-para-title\">L\u2019humanit\u00e9 a longtemps pr\u00e9par\u00e9 ses m\u00e9dicaments \u00e0 partir de plantes<\/h2><p class=\"intro-para-content\">Puis la pr\u00e9paration des m\u00e9dicaments a \u00e9volu\u00e9 au fur et \u00e0 mesure du progr\u00e8s scientifique et du d\u00e9veloppement des technologies.  <\/p><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-group undefined section section--article-content\"><div class=\"article-main-content\"><div class=\"container\"><div class=\"row\"><div class=\"col-12 col-md-11 col-lg-10 offset-md-1 offset-lg-1\"><div class=\"article-text article-quote-text\">\n<figure class=\"wp-block-image alignleft\"><a href=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/04\/PoV_Invent-Digital-Therapeutics_Def.pdf\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/2\/2022\/01\/DTx.png?w=217\" alt=\"Point de vue Digital Therapeutics\" class=\"wp-image-240866\"\/><\/a><\/figure>\n\n\n\n<p>Tr\u00e8s r\u00e9cemment, la crise du COVID-19 a attir\u00e9 l\u2019attention sur une classe de produits th\u00e9rapeutiques appel\u00e9s biologics, illustr\u00e9e par les vaccins \u00e0 ARNm d\u00e9velopp\u00e9s par Pfizer\/BioNTech et Moderna, qui sont bas\u00e9s sur la biologie des technologies de virus inactiv\u00e9 et de vaccins recombinants.<\/p>\n\n\n\n<p>Ces technologies, bas\u00e9es sur la biologie, sont \u00e9galement appliqu\u00e9es en oncologie et en maladies orphelines pour gu\u00e9rir les patients en utilisant la g\u00e9nomique, permettant ainsi l\u2019essor de la th\u00e9rapeutique \u00ab biologique \u00bb.<\/p>\n\n\n\n<p>Alors que cette classe th\u00e9rapeutique est bas\u00e9e sur les sciences naturelles, une autre classe th\u00e9rapeutique bas\u00e9e sur la data science suscite de plus en plus d\u2019int\u00e9r\u00eat ces derni\u00e8res ann\u00e9es : les Digital Therapeutics (DTx).<\/p>\n\n\n\n<p>Elles reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle (imagerie, analyses m\u00e9dicales) soit num\u00e9rique (score cognitif sur un jeu t\u00e9l\u00e9phonique), pour g\u00e9n\u00e9rer un profil patient et ainsi d\u00e9terminer l\u2019intervention optimale pour apporter le meilleur r\u00e9sultat possible pour ce profil de patient, ouvrant ainsi la voie \u00e0 des soins personnalis\u00e9s aux sp\u00e9cificit\u00e9s du patient.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/04\/PoV_Invent-Digital-Therapeutics_Def.pdf\">T\u00e9l\u00e9chargez le Point de Vue<\/a><\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-profile-card undefined profile-card section profile-card-slider\"><div class=\"container profileCardContainer\"><div class=\"profile-box\"><div class=\"row\"><div class=\"col-md-6 col-lg-3\"><div class=\"box\"><div class=\"box-author-img\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Damien-Vossion.jpg?w=500&amp;quality=70\" srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Damien-Vossion.jpg?w=500&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Damien-Vossion.jpg?w=1000&amp;quality=70 2x\" class=\"box-img\" alt=\"\" style=\"object-fit:cover;object-position:50% 50%\" loading=\"lazy\"\/><\/div><\/div><\/div><div class=\"col-md-6 col-lg-9 right-side-box\"><div class=\"row right-box\"><div class=\"col-lg-4 profile\"><h3 class=\"profile-title\">Damien Vossion<\/h3><p class=\"box-position\">Head of Industry &amp; Life Sciences<br>Capgemini Invent<\/p><ul class=\"social-nav social-nav-icons\"><li><a aria-label=\"LinkedIn (en anglais seulement)\" href=\"https:\/\/fr.linkedin.com\/in\/damien-vossion-5197a9\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"icon-li\" aria-hidden=\"true\"><\/i><\/a><\/li><\/ul><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-profile-card undefined profile-card section profile-card-slider\"><div class=\"container profileCardContainer\"><div class=\"profile-box\"><div class=\"row\"><div class=\"col-md-6 col-lg-3\"><div class=\"box\"><div class=\"box-author-img\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Barnabe-Lecouteux.jpg?w=500&amp;quality=70\" srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Barnabe-Lecouteux.jpg?w=500&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/06\/Barnabe-Lecouteux.jpg?w=1000&amp;quality=70 2x\" class=\"box-img\" alt=\"\" style=\"object-fit:cover;object-position:50% 50%\" loading=\"lazy\"\/><\/div><\/div><\/div><div class=\"col-md-6 col-lg-9 right-side-box\"><div class=\"row right-box\"><div class=\"col-lg-4 profile\"><h3 class=\"profile-title\">Barnab\u00e9 Lecouteux<\/h3><p class=\"box-position\">Principal AI &amp; Data services<br>Capgemini Invent<\/p><ul class=\"social-nav social-nav-icons\"><li><a aria-label=\"LinkedIn (en anglais seulement)\" href=\"https:\/\/www.linkedin.com\/in\/barnab%C3%A9-lecouteux-a9a31ba\/\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"icon-li\" aria-hidden=\"true\"><\/i><\/a><\/li><\/ul><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n\n\n\n<section class=\"wp-block-cg-blocks-profile-card undefined profile-card section profile-card-slider\"><div class=\"container profileCardContainer\"><div class=\"profile-box\"><div class=\"row\"><div class=\"col-md-6 col-lg-3\"><div class=\"box\"><div class=\"box-author-img\"><img decoding=\"async\" src=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/Aymeric-Colleville.jpg?w=500&amp;quality=70\" srcset=\"https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/Aymeric-Colleville.jpg?w=500&amp;quality=70 1x, https:\/\/www.capgemini.com\/fr-fr\/wp-content\/uploads\/sites\/6\/2022\/01\/Aymeric-Colleville.jpg?w=1000&amp;quality=70 2x\" class=\"box-img\" alt=\"\" style=\"object-fit:cover;object-position:50% 50%\" loading=\"lazy\"\/><\/div><\/div><\/div><div class=\"col-md-6 col-lg-9 right-side-box\"><div class=\"row right-box\"><div class=\"col-lg-4 profile\"><h3 class=\"profile-title\">Aymeric Colleville<\/h3><p class=\"box-position\">Managing Consultant &amp; DTx expert<br>Capgemini Invent<\/p><ul class=\"social-nav social-nav-icons\"><li><a aria-label=\"LinkedIn (en anglais seulement)\" href=\"https:\/\/fr.linkedin.com\/in\/aymericcolleville\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"icon-li\" aria-hidden=\"true\"><\/i><\/a><\/li><\/ul><\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;humanit\u00e9 a longtemps pr\u00e9par\u00e9 ses m\u00e9dicaments \u00e0 partir de plantes.<br \/>\nPuis la pr\u00e9paration des m\u00e9dicaments a \u00e9volu\u00e9 au fur et \u00e0 mesure du progr\u00e8s scientifique et du d\u00e9veloppement des technologies.<\/p>\n","protected":false},"author":157,"featured_media":6693,"template":"","meta":{"cg_dt_proposed_to":[],"cg_seo_hreflang_relations":"[]","cg_seo_canonical_relation":"{\"uuid\":\"5f763163-c4f4-42c6-9118-31fecbedb352\",\"blogId\":\"\",\"domain\":\"\",\"sitePath\":\"\",\"postLink\":\"\",\"postId\":null,\"isSaved\":true,\"isCrossLink\":false,\"hasCrossLink\":false}","cg_seo_hreflang_x_default_relation":"{\"uuid\":\"49a8f474-4db8-4ef8-b0e5-db4b8239fb64\",\"blogId\":\"\",\"domain\":\"\",\"sitePath\":\"\",\"postLink\":\"\",\"postId\":null,\"isSaved\":true,\"isCrossLink\":false,\"hasCrossLink\":false}","cg_dt_approved_content":true,"cg_dt_mandatory_content":false,"cg_dt_notes":"","cg_dg_source_changed":false,"cg_dt_link_disabled":false,"footnotes":"","related_resource_url":"","related_resource_id":0,"related_resource_size":"","related_resource_type":"","cg_author":0,"_yoast_wpseo_primary_theme":0,"primary_term":"","featured_focal_points":""},"tags":[158,180],"research-and-insight-type":[159],"theme":[],"brand":[160],"service":[],"industry":[119],"partners":[],"content-group":[],"class_list":["post-6692","research-and-insight","type-research-and-insight","status-publish","has-post-thumbnail","hentry","tag-life-sciences","tag-sante","research-and-insight-type-points-de-vue","brand-capgemini-invent","industry-life-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.8 (Yoast SEO v22.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical - Capgemini Canada French<\/title>\n<meta name=\"description\" content=\"Les digital therapeutics reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle, soit de mani\u00e8re num\u00e9rique\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/digital-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical\" \/>\n<meta property=\"og:description\" content=\"Les digital therapeutics reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle, soit de mani\u00e8re num\u00e9rique\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Capgemini Canada French\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-09T06:22:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2025\/10\/New-Web-preview-global.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/\",\"url\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/\",\"name\":\"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical - Capgemini Canada French\",\"isPartOf\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg\",\"datePublished\":\"2022-01-13T17:42:00+00:00\",\"dateModified\":\"2023-11-09T06:22:37+00:00\",\"description\":\"Les digital therapeutics reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle, soit de mani\u00e8re num\u00e9rique\",\"breadcrumb\":{\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#primaryimage\",\"url\":\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg\",\"contentUrl\":\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg\",\"width\":588,\"height\":830},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.capgemini.com\/ca-fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research &amp; insights\",\"item\":\"https:\/\/www.capgemini.com\/ca-fr\/research-and-insight\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.capgemini.com\/ca-fr\/#website\",\"url\":\"https:\/\/www.capgemini.com\/ca-fr\/\",\"name\":\"Capgemini Canada French\",\"description\":\"Capgemini\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.capgemini.com\/ca-fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical - Capgemini Canada French","description":"Les digital therapeutics reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle, soit de mani\u00e8re num\u00e9rique","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.capgemini.com\/fr-fr\/perspectives\/publications\/digital-therapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical","og_description":"Les digital therapeutics reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle, soit de mani\u00e8re num\u00e9rique","og_url":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/","og_site_name":"Capgemini Canada French","article_modified_time":"2023-11-09T06:22:37+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2025\/10\/New-Web-preview-global.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/","url":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/","name":"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical - Capgemini Canada French","isPartOf":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg","datePublished":"2022-01-13T17:42:00+00:00","dateModified":"2023-11-09T06:22:37+00:00","description":"Les digital therapeutics reposent sur l\u2019analyse de biomarqueurs, g\u00e9n\u00e9r\u00e9s de mani\u00e8re soit traditionnelle, soit de mani\u00e8re num\u00e9rique","breadcrumb":{"@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#primaryimage","url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg","contentUrl":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg","width":588,"height":830},{"@type":"BreadcrumbList","@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.capgemini.com\/ca-fr\/"},{"@type":"ListItem","position":2,"name":"Research &amp; insights","item":"https:\/\/www.capgemini.com\/ca-fr\/research-and-insight\/"},{"@type":"ListItem","position":3,"name":"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical"}]},{"@type":"WebSite","@id":"https:\/\/www.capgemini.com\/ca-fr\/#website","url":"https:\/\/www.capgemini.com\/ca-fr\/","name":"Capgemini Canada French","description":"Capgemini","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.capgemini.com\/ca-fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"}]}},"theme_term_info":[],"industry_term_info":[{"id":119,"name":"Life sciences"}],"services_term_info":[],"partners_term_info":[],"brand_term_info":[{"id":160,"name":"Capgemini Invent","slug":"capgemini-invent"}],"brand_term":[{"id":160,"slug":"capgemini-invent"}],"parsely":{"version":"1.1.0","canonical_url":"https:\/\/capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/","smart_links":{"inbound":0,"outbound":0},"traffic_boost_suggestions_count":0,"meta":{"@context":"https:\/\/schema.org","@type":"NewsArticle","headline":"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical","url":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/"},"thumbnailUrl":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg?w=150&h=150&crop=1","image":{"@type":"ImageObject","url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg"},"articleSection":"Uncategorized","author":[],"creator":[],"publisher":{"@type":"Organization","name":"Capgemini Canada French","logo":""},"keywords":["life sciences","sant\u00e9"],"dateCreated":"2022-01-13T17:42:00Z","datePublished":"2022-01-13T17:42:00Z","dateModified":"2023-11-09T06:22:37Z"},"rendered":"<meta name=\"parsely-title\" content=\"Des plantes aux donn\u00e9es \u2013 une nouvelle classe th\u00e9rapeutique dans l\u2019arsenal m\u00e9dical\" \/>\n<meta name=\"parsely-link\" content=\"https:\/\/www.capgemini.com\/ca-fr\/perspectives\/publications\/digital-therapeutics\/\" \/>\n<meta name=\"parsely-type\" content=\"post\" \/>\n<meta name=\"parsely-image-url\" content=\"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg?w=150&amp;h=150&amp;crop=1\" \/>\n<meta name=\"parsely-pub-date\" content=\"2022-01-13T17:42:00Z\" \/>\n<meta name=\"parsely-section\" content=\"Uncategorized\" \/>\n<meta name=\"parsely-tags\" content=\"life sciences,sant\u00e9\" \/>","tracker_url":"https:\/\/cdn.parsely.com\/keys\/capgemini.com\/p.js"},"archive_status":false,"featured_image_src":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg","featured_image_alt":"","jetpack_sharing_enabled":true,"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Capgemini Canada French","distributor_original_site_url":"https:\/\/www.capgemini.com\/ca-fr","push-errors":false,"tag_names":["Life Sciences","Sant\u00e9"],"featured_image_url":"https:\/\/www.capgemini.com\/ca-fr\/wp-content\/uploads\/sites\/21\/2022\/01\/2022-FR-Featured-Image-PoV-DTx.jpg","_links":{"self":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/research-and-insight\/6692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/research-and-insight"}],"about":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/types\/research-and-insight"}],"author":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/users\/157"}],"version-history":[{"count":8,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/research-and-insight\/6692\/revisions"}],"predecessor-version":[{"id":705561,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/research-and-insight\/6692\/revisions\/705561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/media\/6693"}],"wp:attachment":[{"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/media?parent=6692"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/tags?post=6692"},{"taxonomy":"research-and-insight-type","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/research-and-insight-type?post=6692"},{"taxonomy":"theme","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/theme?post=6692"},{"taxonomy":"brand","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/brand?post=6692"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/service?post=6692"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/industry?post=6692"},{"taxonomy":"partners","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/partners?post=6692"},{"taxonomy":"content-group","embeddable":true,"href":"https:\/\/www.capgemini.com\/ca-fr\/wp-json\/wp\/v2\/content-group?post=6692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}